Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-076550
Filing Date
2026-02-26
Accepted
2026-02-26 16:06:08
Documents
98
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K ntla-20251231.htm   iXBRL 10-K 3674262
2 EX-3.1 ntla-ex3_1.htm EX-3.1 106375
3 EX-10.25 ntla-ex10_25.htm EX-10.25 44884
4 EX-10.29 ntla-ex10_29.htm EX-10.29 15206
5 EX-21.1 ntla-ex21_1.htm EX-21.1 5580
6 EX-23.1 ntla-ex23_1.htm EX-23.1 4461
7 EX-31.1 ntla-ex31_1.htm EX-31.1 15171
8 EX-31.2 ntla-ex31_2.htm EX-31.2 15191
9 EX-32.1 ntla-ex32_1.htm EX-32.1 10131
10 GRAPHIC img222752881_0.gif GRAPHIC 3672
11 GRAPHIC img246447493_0.jpg GRAPHIC 235945
12 GRAPHIC img246447493_1.jpg GRAPHIC 675659
  Complete submission text file 0001193125-26-076550.txt   16714922

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20251231.xsd EX-101.SCH 1828877
101 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20251231_htm.xml XML 2657696
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37766 | Film No.: 26687833
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)